Issue 58, 2016

Therapeutic potential of a synthetic FABP4 inhibitor 8g on atherosclerosis in ApoE-deficient mice: the inhibition of lipid accumulation and inflammation

Abstract

Fatty-acid-binding proteins are small (14–15 kDa) proteins that bind reversibly with high affinity to hydrophobic ligands. Fatty-acid-binding protein 4 (FABP4), highly expressed in adipocytes and macrophages, plays an essential regulatory role in energy metabolism and inflammation. In a previous study, we reported N-(2-(4-(1-allyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo(3,2-d)pyrimidin-6-yl)phenoxy)ethyl)picolinamide (8g), as an effective agent to prevent non-alcoholic fatty liver disease (NAFLD). In the present study, we found 8g to be a novel FABP4 inhibitor that significantly inhibited triglyceride accumulation and the expression of Fabp4 in 3T3-L1 adipocytes. In macrophages, 8g inhibited both Fabp4 and pro-inflammatory cytokine production. Importantly, in a co-culture system of adipocytes and macrophages, which mimics the functional interaction between adipocytes and macrophages within adipose tissue, 8g inhibited the expression of Fabp4 and cytokine production, and downregulated FABP4 and stress kinases. In line with the in vitro results, 8g markedly and dose-dependently decreased the expression of serum FABP4 and atherosclerotic lesion area in apolipoprotein E-deficient (ApoE-deficient) mice, and significantly reduced epididymal fat mass and plasma levels of triglycerides in diet-induced obesity (DIO) mice. All together, 8g is a novel FABP4 inhibitor demonstrated to ameliorate atherosclerosis through the reduction of lipid accumulation and inflammatory response, which may offer a potent therapeutic strategy against atherosclerosis and obesity.

Graphical abstract: Therapeutic potential of a synthetic FABP4 inhibitor 8g on atherosclerosis in ApoE-deficient mice: the inhibition of lipid accumulation and inflammation

Associated articles

Supplementary files

Article information

Article type
Paper
Submitted
03 Mar 2016
Accepted
09 May 2016
First published
11 May 2016

RSC Adv., 2016,6, 52518-52527

Therapeutic potential of a synthetic FABP4 inhibitor 8g on atherosclerosis in ApoE-deficient mice: the inhibition of lipid accumulation and inflammation

H. Pei, C. Xie, Y. Liu, M. Shao, J. Chen, D. Li, L. Ma and L. Chen, RSC Adv., 2016, 6, 52518 DOI: 10.1039/C6RA05637G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements